Can a Triple-Drug combo tame acute myeloid leukemia in frail patients?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1\. Patients meeting the World Health Organization (WHO) 2016 diagnostic criteria for newly diagnosed acute myeloid leukemia (AML) patients unfit for intensive chemotherapy: 1. Age ≥65 years, or 2. Age \>18 years and ineligible for standard-dose chemotherapy, defined by ≥1 of the following: ECOG performance status 2 or 3；History of chronic heart failure (CHF) requiring treatment or left ventricular ejection fraction (LVEF) ≤50% DLCO ≤65% or FEV1 ≤65%Creatinine clearance ≥30 mL/min but ≤45 mL/min (Cockcroft-Gault)、Any other condition deemed incompatible with standard chemotherapy (requires PI approval) 2. No prior AML therapy, except:Hydroxyurea. 3. ECOG performance status ≤3 4. Laboratory requirements: WBC≤3×10\*9/L、AST/ALT/ALP ≤3×ULN (except: due to leukemic involvement)、Total bilirubin ≤1.5×ULN、Serum creatinine clearance ≥30 mL/min (measured or calculated) 5. Life expectancy ≥3 months 6. Contraception requirements: Negative pregnancy test for women of childbearing potential；Agreement to use effective contraception during treatment and for 6 months after therapy Exclusion Criteria: 1. AML with BCR::ABL1 fusion、Acute promyelocytic leukemia (APL). 2. Secondary AML, including:Therapy-related AML (per WHO classification)、AML with prior history of myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN). 3. Use of strong/moderate CYP3A4 inducers within 3 days prior to treatment initiation. 4. Hypersensitivity to any study drugs. 5. Active malignancy in other organs (requiring treatment). 6. Active cardiac disease, defined as ≥1 of the following:Myocardial infarction within 6 months before enrollment；History of symptomatic arrhythmia requiring medication；Uncontrolled/symptomatic congestive heart failure (NYHA Class \>2) 7. Active infections, including:Untreated tuberculosis or any aspergillosis. 8. Known HIV, active hepatitis B (HBV), or hepatitis C (HCV). 9. Central nervous system (CNS) leukemia at baseline. 10. Conditions limiting oral drug absorption (e.g., malabsorption syndrome). 11. Medical history of:Epilepsy requiring medication、Dementia or psychiatric disorders impairing protocol compliance. 12. Investigator's discretion for ineligibility.